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                                                       ABSTRACT    
                                               
                   
                    Influenza is a contagious respiratory disease causing mild to severe illness.  The 
emergence of a new Influenza virus H1N1 pandemic stain in 2009 has increased the risk of 
another pandemic.  Some concern regarding the potential resistance to neuraminidase 
inhibitors, along with concerns regarding a readily available vaccine to target emerging 
viruses, and insufficient evidence to recommend use of antibiotics for upper respiratory tract 
infection (Aroll B et al, 2005),  have motivated researchers  to look for alternative medicines 
and other therapies including herbal remedies. Plants species belonging to Genus Echinacea 
are among the most extensively used herbal remedies for “flu- like” symptoms, and are also 
known to be used traditionally in North Americans native populations for respiratory illness, 
wounds, digestive problems, and poisoning (Felter et al., 1983, Hobbs, 1994). Recent 
research on Echinacea species has been primarily focused on the immune modulatory 
properties, particularly in preventing and treating respiratory tract infection (Barnes et al., 
2005). Several studies using Echinacea extract treatments have reported beneficial effects in 
preventing and treating respiratory tract infections such as influenza or rhinovirus infections, 
but the efficacy of Echinacea is debatable due to inconsistent findings. In this dissertation, 
we report the results of investigation into the effect of different extracts prepared from two 
commonly used Echinacea species, E. angustifolia and E. purpurea.  The in vivo disease 
model used to test the efficacy of these extracts is a murine model of influenza infection.  
Both aqueous and ethanol extracts from E. angustifolia and E. purpurea were tested in mice 
subsequently infected with influenza virus. All extracts tested harbored some level of 
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immune modulatory potential, but showed large variability based on plant species and 
extraction method used.  Aqueous extracts from both species of Echinacea demonstrated 
greater stimulatory effects on immune responses than did ethanol extracts.  The most striking 
effects were improved survival rate and increase in wide range of cytokine/chemokines in the 
lungs by water extracts. With respect to a species effect, E. angustifolia extracts tended to 
have more potent activity than E. purpurea extracts and this held true for both water and 
ethanol extracts.  Modulation of specific cell populations in the lung was also found, but this 
effect varied by type of extract.  In spite of these immunomodulatory changes, there was no 
reduction in the lung viral load, or any change in weight loss or food intake up to day 8 post-
infection.                                   
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                                  CHAPTER ONE: GENERAL INTRODUCTION 
 
Literature Review 
              In recent years, there has been renewed interest in evaluating the pharmacological 
and physiochemical properties of botanicals, including one of the most commonly used 
products, Echinacea. The immunomodulatory properties of Echinacea are the main focus of 
research, although other potential activities such as anti-viral (Binns et al., 2002; Ghaemi et 
al., 2008; Birt, 2008), anti-fungal (Morazzoni et al., 2005), and antioxidant properties 
(Mishima et al., 2004; Dalby-brown et al., 2005) have also been documented.  However, 
there are still many challenges before Echinacea can be recommended for medicinal 
purposes due to inconsistent results. The variability of results regarding the ability of 
Echinacea to modify the outcome of infection can be partly attributed to lack of standardized 
Echinacea extracts, along with the use of different models of infection, and/or different in 
vitro systems used to assess pharmacological properties (Hudson et al., 2005; Wolkert K., 
2008; Vimalanathan et al., 2009). In subsequent sections, we will examine literature related 
to properties of Echinacea species and its effectiveness as an immunomodulator particularly 
in relation to influenza infection. 
 
Phytoactive compounds and their variability 
              Extracts obtained from Echinacea plants are a mixture of compounds that can 
be broadly characterized as alkamides, caffeic acid derivatives (cichoric, chlorogenic and 
cafeolytattaric acid), glycoproteins or polysaccharides (arabinogalactans, fructofuranosides, 
heteroxylans).  Each constituent has shown individual bioactivity and contributes to the 
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pharmacological activity of a given extract, but the concentration of each constituent is 
variable depending on the Echinacea species, plant organ used for extraction (e.g., roots, 
stems, aerial portions), growing condition (Sloley et al., 2001; Gray et al., 2003), and method 
of extraction (Hall et al., 2003; Perry et al., 2001).  Only three out of nine known species of 
Echinacea have been studied extensively for their medicinal properties, and few studies 
directly compare the constituent profile and pharmacological properties of these species. 
Bioactive compound accumulation in the plant has been shown to be dependent on organ 
type and age of the plant (Wu et al., 2004; Barnes et al., 2005). In research conducted by 
Binns et al. (2002a), the quantitative phytochemical diversity of all species in genus 
Echinacea was assessed, and the results showed that differences in constituents across 
species accounted for a range of activities in Echinacea extracts.  These studies also revealed 
the presence of the highest amount of cichoric acid in the flower portion of E. pallida, 
whereas E. purpurea roots had the highest quantities of alkamides.  As an example of varied 
bioactivity by species, Binns et al., (2002b) demonstrated that 70% ethanol extract of E. 
pallida roots exhibited the most potent inhibition of herpes simplex virus grown on Vero 
cells, followed by cichoric acid and E. purpurea root extract.   
              In separate studies, Barnes et al., (2005) documented the presence of two 
structurally different kinds of alkamides in E. angustifolia and E. purpurea, but an absence of 
alkamides in E. pallida. Other recent studies have demonstrated the presence of alkamides in 
extracts of Echinacea species as the main contributor to anti-inflammatory activity (reduced 
PGE2 production from LPS stimulated RAW cells) (Lalone et al., 2007).  In addition to the 
bioactivity attributed to alkamides, it has been shown that polyphenolic compounds may also 
have bioactivity.  A study by Pellati et al., (2004) quantified the phenolic composition in 
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multiple Echinacea species using a Lichrospher RP-18 (RP-LC) method and measured 
radical scavenging activity.  Their results suggested that the anti-oxidant effect was greatest 
in extracts derived from E. purpurea, and they concluded that E. purpurea has a higher 
phenolic content than other Echinacea species. Another constituent, cynarin, (a 
phenylpropanoid) has been shown to block CD28 dependent activation of T lymphocytes 
(Dong et al., 2009), and this constituent has been shown to be present in E. angustifolia roots 
but not in other Echinacea species (Sloley et al., 2001).  In addition to alkamides and caffeic 
acid, polysaccharides present in Echinacea extracts were also shown to be bioactive (Bauer 
et al., 1998). Polysaccharide rich Echinacea extracts have been shown to activate non-
specific innate immune response to antigenic stimuli (Sullivan et al., 2008; Morazzoni et al., 
2005; Pillai et al., 2007). Others have concluded that arabinogalactan-containing 
glycoproteins and high molecular mass polysaccharides present in Echinacea extracts are 
responsible for the varied range of immune-stimulatory activity and again, these components 
all vary by species (Classen et al., 2006). 
              The extraction process also plays a major role in determining the concentration of 
constituents. Alkamides are the main hydrophobic component of plant root extracts and 
ethanol extraction results in greater concentrations of alkamides, whereas the more 
hydrophilic polysaccharides are retained in water extracts (Bauer et al., 1998; Hall et al., 
2003). Phenolic compounds may be extracted by water-alcohol extraction methods and are 
also present separately in water and ethanol extracts (Perry et al., 2001). The extraction 
method and resulting compounds isolated are of major importance with respect to the 
biological activity.  For example, in a recent study, opposite results were found regarding the 
immunomodulatory activity of Echinacea extracts depending upon extraction method and 
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plant part used. Benson et al., (2010) compared the effects of different extracts of E. 
purpurea on murine dendritic cell function. The results showed that polysaccharide rich root 
extract increased the expression of cell surface bio-markers (MHC II, CD86, CD54) and 
production of pro-inflammatory cytokines (IL-6, TNFα) whereas alkamide-rich leaf extracts 
inhibited the expression of both cell surface biomarkers and cytokine production. These 
findings illustrate that the immunomodulatory effects of Echinacea may be linked to the 
portion of plant and extraction method used.  
  
Echinacea as immunomodulator 
  Earlier literature described Echinacea as immunostimulatory (Burger et al., 1997) 
but in view of more recent reports, the term “immunomodulatory” may be a more appropriate 
term to describe the effect of Echinacea on the immune cells. A wide range of 
immunological parameters (both in vivo and in vitro) have been measured with respect to the 
effect of Echinacea. However, there is no consensus regarding the exact mechanisms of 
action by which Echinacea alters immune response.  The lack of consensus is most likely due 
to a lack of standardized preparation and variability in the models chosen to study immune 
response. The mechanisms by which Echinacea is effective in modulating the immune 
response are still elusive, but it is possible to identify general patterns of response based on 
current literature.   
              Overall it appears that Echinacea has greater immunodulatory effects on innate 
immunity as compared to adaptive immune responses.  However, adaptive immune responses 
have been less well studied and, therefore, the lack of data showing effects on adaptive 
immunity may simply be a result of less information rather than no effect.  Although 
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infection models are limited, one study showed that E. purpurea polysaccharides reduced the 
bacterial load in Listeria monocytogenes-infected mice, and this activity was attributed to 
increased macrophage cytokine production.  Also, in a herpes simplex infection model, the 
polysaccharide fraction of Echinacea showed anti-viral effects against Herpes Simplex virus, 
and this effect may have involved increased IFNγ production induced by polysaccharides 
(Ghaemi et al., 2008).  Numerous other studies have shown that the polysaccharide rich 
fractions of Echinacea tend to exhibit the greatest immunostimulatory activity.  For example, 
Sullivan et al., (2008) in an in vitro study demonstrated activation of peritoneal macrophages 
by E. purpurea polysaccharides resulting in increased production of inflammatory cytokines 
(TNFα, IL-1α, IL-6, and IL-12) and nitric oxide (NO). Similar results (increased IL-1, TNFα, 
IL-10) were observed in an earlier study on human peripheral blood macrophages using E. 
purpurea extract (Burger et al., 1997) and increased TNFα and NO production by alveolar 
and spleen macrophages using water-ethanol extract of E. purpurea (Goel et al., 2002).  
Other data suggests that the greatest immunostimulatory activity (defined as increased 
expression of activation marker CD69 on T cells, NK cells, and B cells) was found in 
polysaccharide rich fractions of E. angustifolia and E. purpurea, but almost no activity was 
found in the fractions containing lipophilic small molecules (echinoacoside, cichoric acid, 
polyenes) extracted with ethanol.  Natural Killer (NK) cells, an important part of anti-viral 
innate response, are also thought to be modulated by use of Echinacea polysaccharides. One 
study conducted using NK cells present in the human peripheral blood mononuclear cell 
population demonstrated that a water extract of Echinacea increased NK cytotoxicity (Gan et 
al., 2003).  In vivo experiments using Echinacea purpurea root extract showed an increase in 
NK cell numbers in the spleen (Currier et al., 2000; Brousseau et al., 2005; Sun et al., 1999; 
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Gan et al., 2003), and also appeared to increase survival rate of the mice by middle age when 
E. purpurea supplemented diet was fed (13 months) (Brousseau, 2005). 
                  In contrast to the findings on polysaccharide rich extracts, alkamide rich ethanolic 
extracts of Echinacea have been shown to stimulate anti-inflammatory cytokines (IL-10) and 
inhibit the secretion of  pro-inflammatory (e.g., TNFα) cytokines from murine macrophage 
cell line (Chen et al., 2005; Chicca et al., 2009; Senchina et al., 2006). Also, data collected 
by Sharma et al., 2009, in a series of experiments using ethanolic extract of E. purpurea 
showed inhibition of pro-inflammatory (e.g., IL-6, IL-8) cytokine production in a virus-
infected human bronchial epithelial cell line. Similar findings showed that the production of 
inflammatory mediators (IL-1β, TNFα, NO ) by Salmonella enterica-infected RAW 264.7 
macrophages and peritoneal exudates macrophages was decreased when cultured with 
ethanol extracts of E. purpurea or E. pallida (Zhai et al., 2007a).  It was also found that 
ethanol extracts of Echinacea exhibited antiviral activity against Herpes Simplex virus grown 
on Vero cells, but the activity varied with extract type and plant species (Binns et al., 2002). 
A recent study on mouse macrophage cells stimulated by LPS identified individual alkamides 
from Echinacea species responsible for inhibition of PGE2 production, an important 
inflammatory mediator, using high performance liquid chromatography (Lalone et al., 2007 
& 2009).  In summary, much of the data published on ethanol extracts and/or alkamide-rich 
fractions has revealed an anti-inflammatory effect.  
               Although most of the work performed to date has used in vitro models, there are 
limited data from in vivo studies that have demonstrated immune modulation of both innate 
and adaptive responses with the use of different Echinacea preparations (Rehman et al., 
1999; Zhai et al., 2007b). Findings from one in vivo study suggested that Echinacea extracts 
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containing varying doses of cichoric acid, polysaccharides, and alkylamides stimulated non-
specific immune responses as evidenced by increased alveolar macrophage TNFα and NO 
release, increased splenocyte IFNγ production, and enhanced phagocytic activity by alveolar 
macrophages in a dose dependent fashion (Goel et al 2002).  A similar study compared 
immunomodulatory effects of ethanol extracts prepared from three different species (E. 
angustifolia, E. purpurea, E. pallida) and found that splenocytes stimulated with ConA had 
greater IL-2 and IL-4 production when cultured with E. angustifolia extract, greater IL-5 
production with E. pallida extract, and reduced IL-1β and TNFα when cultured with LPS 
plus extracts from all 3 species of Echinacea (Zhai et al., 2007b).  Enhancement of adaptive 
immune responses in rats after repeated exposure to keyhole limpet hemocynanin antigen 
was observed by increased antigen-specific immunoglobulin production in conjunction with 
Echinacea treatment (Rehman et al., 1999). Similar results were observed following dietary 
administration of E. purpurea root extract as evidenced by enhanced proliferation of B cell 
and T cell in tumor cell immunized mice (Currier et al., 2002), and increased IgM-specific 
antibody forming cells in mice immunized with sheep red blood cells (Freier et al., 2003). It 
is also possible that changes in adaptive immune response are mediated via Echinacea-
induced modulation of innate immunity.  Recently, findings by Mishima et al. (2004), 
suggested that E. purpurea extract activated macrophage cytokine production, resulting in 
increased T cell proliferation especially CD4
+
 and CD8
+
 T cell subsets in radiation induced 
leukopenic mice.  Therefore, in future studies, it would be worthwhile to determine the extent 
to which the T and B cell changes that occur in Echinacea-treated animals may be due to 
innate activation of cytokines that stimulate T and/or B cell function, as opposed to a direct 
effect on T or B cells.   
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Influenza Virus and Immune response  
               Influenza virus, belonging to the Orthomyxoviridae family, results in acute 
infection causing substantial morbidity and mortality in humans worldwide. In the United 
States, every year, between 5 % - 20 % of the population suffers from respiratory illness 
caused by influenza virus (http://www.cdc.gov/flu/about/disease/index.htm).  Influenza 
viruses also have a zoonotic potential, and are highly contagious for birds, horses, pigs as 
well as humans. Viral hemagglutinin is required for binding to sialic acid on surface of host 
cells determining its tropism (Weis et al., 1988). Influenza virus primarily binds to columnar 
epithelial cells of respiratory tract which also is the site of viral replication (Lamb et al., 
1996). Replication leads to cytopathic effects on epithelial cells characterized by  down- 
regulation of host cell protein synthesis (Katze et al.,1986; Sanz-Esquerro et al., 1995) and 
apoptosis (Wiley et al., 2001) resulting in acute disease onset. In addition, hyperactivity of 
bronchial system (Utell et al., 1980; Little et al., 1978), small airway obstruction (Hall et al., 
1976) and impaired diffusion capacity (Horner et al., 1973) are main contributors to 
respiratory symptoms. Influenza infection also initiates a cascade of nonspecific and adaptive 
immune responses which contribute substantially toward clinical signs and symptoms. 
Respiratory epithelial cells infected by virus respond by producing cytokines/chemokines 
(IFNα/β, IL-1, IL-6, and TNFα) to attract appropriate immune populations to the site of 
infection, but the major source of interferon and pro-inflammatory cytokine production are 
macrophages and dendritic cells which are indirectly stimulated by viral replication (Ronni et 
al., 1997; Sareneva et al., 1998). These inflammatory cytokines (IL-1, IL-6, IL-12, and 
TNFα) may further activate NK cells (Nguyen et al., 2004), induce a febrile response (IL-1β, 
IL-6 and TNFα), and may contribute to immunopathological lesions (Wareing et al., 2004).  
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Infected respiratory epithelial cells along with alveolar macrophages and plasmacytoid 
dendritic cells (pDC) respond by producing type I interferon (Kumagi et al., 2007; Ronni et 
al., 1997; Jewell et al., 2007). Type I interferon’s (IFNα and IFNβ) constitute the first line of 
antiviral response as they induce apoptosis of infected cells and potentiate innate and 
adaptive immune response through activation of NK cells and effector T cells (Stetson & 
Medzhitov., 2006).  Type I interferons also have direct anti-viral activity (Katze et al., 2002).  
Further, apoptotic infected epithelial cells release heat labile factors and chemokines such 
as IL-8 (or KC in the mouse) that promote recruitment of neutrophils and enhance 
phagocytosis by macrophages and neutrophils (Hashimato et al., 2007). Along with these 
cytokines, influenza virus infection results in an upregulated mRNA for MCP-1, MIP-1α, 
MIP-1β, RANTES, IP-10, MIP (neutrophils attractant), and MIP-3α (immature DC) 
(Wareing et al., 2004). These chemokines induce an inflammatory infiltrate comprised of 
mononuclear cells and neutrophils.  
                Both alveolar macrophages and monocyte-derived inflammatory macrophages are 
important in phagocytosis of infected cells, antigen presentation, and production of pro-
inflammatory cytokines and chemokines. Studies of H1N1 influenza virus infection in mice 
have indicated a significant increase in recruitment of macrophages and neutrophils to lungs; 
however, depletion of these cell populations has been shown to increase mortality, suggesting 
that these cell populations may have both an inflammatory and protective role (Tumpey et 
al., 2005).  In addition to the role of monocytes, macrophages, and dendritic cells in 
producing inflammatory cytokines, virus infected mononuclear cells are also an important 
source of IL-12, which is required in early production of IFNγ and induction of cytotoxic T 
lymphocytes responses (but may not be absolutely necessary for recovery from influenza 
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infection) (Monterio et al., 1998). Another important aspect of anti-viral innate immunity 
involves NK cells, which can be detected in pulmonary lymphocyte populations 48 hrs after 
the initiation of influenza virus infection. NK cells produce IFNγ which may block virus 
spread by lysis of virus infected cells (Biron et al., 1999). Influenza virus infection of mice 
lacking NKp46, a NK cell receptor, results in increased mortality demonstrating the 
importance of NK cells in anti-viral immune response (Gazit et al., 2006).  
               Mononuclear cells are essential for effective induction of adaptive immune 
response and preventing secondary bacterial infection (Brion et al., 1999; Legge et al., 2003) 
but the role of neutrophils in altering the course of infection is not fully understood. Some 
studies have suggested that neutrophils do not play any role in viral clearance (Wareing et 
al., 2007) although excessive neutrophil influx may contribute to lung tissue injury (Sakai et 
al., 2000). A recent study has shown exacerbation of mild disease in the absence of, or with 
impaired neutrophil influx (Tate et al., 2009). In summary, multiple inflammatory cell 
populations are recruited to the lungs early during influenza infection that contribute to 
activation of NK cells and subsequent T cell and B cell responses through cytokine 
production, but may also contribute to immune-mediated pathology. 
              Optimal induction of innate response not only prevents the dissemination of virus 
but also promotes effective adaptive immune responses. Dendritic cells have shown to be 
essential in bridging innate and adaptive immune response. There are two major subtypes of 
DCs: plasmacytoid DC (pDC), which primarily produces IFNα in response to influenza 
infection whereas the conventional DCs (cDC) subtype undergoes maturation after infection 
and migrates to draining lymph nodes for antigen presentation (Grayson et al., 2007).  In 
addition to these functions, both subtypes of DCs produce chemokines and cytokines in 
11 
 
successive waves coordinating the recruitment of NK cells and neutrophils in the acute phase 
and T and B cells in later phase of influenza infection (Piqueras et al., 2006). Subset of DC 
producing TNF and iNOS have been shown to accumulate in lungs infected with lethal dose 
of influenza virus and are required in proliferation of influenza specific CD 8
+  
T cells in 
lungs (Aldridge et al., 2009).
       
 
              Cytokines such as IL-12 and IFNγ produced by antigen presenting cells (APC’s) in 
the presence of antigen results in differentiation of naïve CD4
+
 cells into T helper 1 (Th1) 
cells (Abbas et al., 1996).  Influenza virus infection predominantly induces a Th1 response, 
and CD4
+
 Th1 cells primarily secrete IL-2, TNFα, and IFNγ which promotes proliferation of 
CD8
+
 CTL (Mosmann et al., 1996; Ridge et al., 1998; Riberdy et al., 2000).  These cytokines 
also enhance macrophage function and B cell differentiation to preferentially secrete IgG2a 
antibody (Ada et al., 1986). Cytotoxic CD8
+
 T cells are essential in influenza virus clearance, 
and the primary lytic pathways involve perforin release and Fas cytotoxic mechanism 
(Topham et al., 1997). In localized influenza infection, CD4
+
 cells also play a major role by 
maintaining cytolytic T cell function and the transition to immune memory (Belz et al., 
2002).  In summary, the immune response to influenza involves multiple host defense 
mechanisms, ranging from early innate defenses that may restrict viral spread to 
enhancement of inflammatory pathways that serve to activate appropriate adaptive immune 
responses. 
  
Echinacea in Influenza Infection  
              In the literature, there are reports of several clinical and experimental studies that 
have been conducted to evaluate the use of Echinacea in upper respiratory tract infection.   
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However, the results are inconclusive, as some studies have found a beneficial effect of 
Echinacea on symptoms and the severity of infection (Berg et al.,1998; Brinkeborn et 
al.,1999;Freier et al.,2003; Goel et al.,2004&2005; Hall et al.,2006; Hoheisel et al.,1997; 
Lindenmuth et al.,2000; Melchart et al.,2000, Saunders et al., 2007) while others show no 
reduction in severity of symptoms with use of Echinacea (Barrett et al.,2002;Classen et 
al.,2006; Grimm et al.,1999; Taylor et al.,2003; Turner et al.,2000&2005, O’Neil et al., 
2008; Schwarz et al.,02; Sperber et al.,2004). While much of the previous work has involved 
cell lines, ex vivo studies, or symptomatic evaluation of human subjects, there are only few 
studies exploring the effects of different Echinacea extracts on immune response in vivo.  A 
recent study by Fusco et al., (2010) investigated the effect of neutral and weak acidic 
polysaccharide extract prepared from aerial part of E. purpurea on a murine model of 
influenza A infection. The investigators observed less weight loss in the Echinacea-treated 
mice but no change in viral titer, suggesting a modifying effect of the extract on clinical 
course of infection (less body weight loss) without any evident anti-viral effect.  In this same 
study, at the early phase of infection (day 3), increased IFNγ, IL-12, KC in both lung and 
serum and increased IL-10 only in serum was found in Echinacea treated mice.  By day 7 
post-infection, Echinacea treatment resulted in reduced IL-10 in serum and lung, as well as 
decreased serum IFNγ.  It is not clear from this study how immunomodulatory changes might 
relate to the reduction in weight loss, or to specific immunopathology in the lungs. Only one 
other published study using influenza challenge of mice examined the effect of plant extract 
mixture which included Echinacea as well as Baptisia tinctoria and Thuja occidentalis 
(Bodinet et al., 2002).  The combination of extracts used in this study resulted in an 
improved survival rate, and reduced lung lesion score and viral titer.  Although there was a 
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benefit in terms of a reduction in the infection severity, it is difficult to draw any conclusions 
from the study regarding the specific role of Echinacea because the treatment included a mix 
of herbal remedies, rather than Echinacea alone (Bodinet et al., 2002).  
              The purpose of our present investigation was to verify the specific 
immunomodulatory effects Echinacea species alone (without other herbal constituents) in an 
animal model of influenza infection.  In addition, we sought to determine whether the 
immunomodulatory effects of two commonly used species of Echinacea: E. purpurea and E. 
angustifolia, are consistent or variable. Last, we evaluated the effect of water extracts 
compared to ethanol extracts prepared from E. purpurea and E. angustifolia. The hypothesis 
to be tested was that polysaccharide rich aqueous extract of both Echinacea species would be 
more effective than ethanolic extract of the same Echinacea species in stimulating an 
immune response following an influenza virus infection in mice. We focused on innate 
immune responses for two reasons.  The majority of published data demonstrated potent 
effects on innate immunity, and secondly, adaptive immune responses are largely dependent 
upon appropriate activation of innate host defense. This hypothesis was tested by gavaging 
mice with extract or vehicle 2 days before infection with influenza virus, and continuing 
gavage with extract or vehicle throughout the course of infection until the time at which mice 
were euthanized. Experiments evaluate host responses and viral titer at both acute phase and 
late phases of infection to establish the effect on lung pathology, cytokine/chemokines 
analysis, illness markers, and viral titer and pulmonary cell populations.                                              
                                  
14 
 
Hypothesis 
       
              It is hypothesized that polysaccharide rich aqueous extract of two Echinacea 
species; E. purpurea and E. angustifolia, would be more effective than ethanolic extract of 
the same Echinacea species in stimulating an immune response following an influenza virus 
infection in mice.  To test this hypothesis, an in vivo murine model of influenza A virus 
infection was used, with immune responses assessed at multiple time points post-infection. 
We expect that polysaccharide rich water extract will have greater stimulatory effect on 
immune response as compared to alkamide rich ethanol extracts.  In particular, we expect 
that cytokine and chemokine production will be increased in the lungs of water extract 
treated mice as compared to ethanol extract treated mice.  We also expect that this increase in 
lung cytokine/chemokine production will be accompanied by improved survival, decreased 
lung viral load and reduced symptom severity.  
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CHAPTER TWO:  IMMUNOMODULATORY PROPERTY OF WATER  
                               AND ETHANOL EXTRACTS FROM ECHINACEA  
                               SPECIES.                                                                                                                                                           
 
Abstract  
              Echinacea species have been used traditionally for their medicinal properties. In 
today’s world, Echinacea is one of highest selling herbal medicines consumed primarily for 
its immune modulator properties, particularly in preventing and treating respiratory tract 
infection.  Multiple in vitro studies of Echinacea have been conducted and demonstrate 
immune modulatory effects. However, the results from in vivo studies have shown greater 
disparity, both human clinical trials as well as animal infection models.  Many in vivo studies 
fail to simultaneously evaluate immune response, viral load, and symptoms, and therefore it 
is difficult to determine whether any immune alterations truly have a benefit.  In this study, 
the effects of Echinacea extracts from different species (E. angustifolia and E. purpurea) and 
extraction method (water and ethanol) were compared for their potential effects on 
respiratory immune parameters, viral load in the lungs, and clinical symptoms. It was 
hypothesized that aqueous extracts of Echinacea (rich in polysaccharides) would be more 
effective in stimulating immune responses during influenza infection than ethanol of same 
species. Mice were gavaged with extracts every 24 hrs starting two days prior to infection 
and continued during infection until mice were euthanized. Mice were infected with 
influenza A/PR/8/34 (H1N1) through an intranasal route. Both early and later phases of 
infection were evaluated.  Aqueous extracts, particularly from E. angustifolia had the greatest 
immunostimulatory effect in terms of increased cytokines and chemokines in 
bronchoalveolar lavage (BAL) fluid and improved survival rate of infected mice.  Lung cell 
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populations were altered, but this effect varied by extract and species.  Also, the number of 
influenza-responsive IFNγ producing CD8+ cells present in the BAL fluid was altered by 
Echinacea treatment, but again this effect varied by extract type such that ethanol extracts 
decreased the number of these cells, whereas water extracts significantly increase the number 
of these cells.  There was no effect of any extract on viral load or symptoms (body weight 
loss, food intake), although decreased mortality was seen in mice treated with aqueous 
extract. These results suggest that aqueous extracts of Echinacea have more potential than 
ethanol extracts for modulating the immune response to influenza virus infection, but do not 
demonstrate direct anti-viral activity. 
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Introduction 
              Echinacea had been historically used by Native Americans as an herbal medicine 
with a wide range of pharmacological properties including antimicrobial, analgesic, snakebite 
antidote, and the common cold (Felter et al., 1983; Hobbs, 1994). In the present time, 
Echinacea is one of most common herbal medicines primarily used to alleviate common cold 
symptoms and upper respiratory tract infection especially particularly rhinovirus and 
influenza virus infections (Caruso et al., 2005). The genus Echinacea is composed of 9 
species but typically only 3 (E. angustifolia, E. purpurea, E. pallida) are used and studied for 
potential medicinal properties.  Each of these 3 species has shown immunomodulatory 
potential (Barnes et al., 2005). Each species also has different phytoactive compounds, and 
the amount of these compounds is dependent upon plant organ used, growing condition of 
plants, and method of extract preparation (Perry et al., 2001).  The efficacy of Echinacea as a 
therapeutic agent during influenza infection has not been clearly established.  Although 
multiple studies have examined the immunomodulatory effects of Echinacea with in vitro 
models or ex vivo models, the effectiveness of Echinacea administration and the potential 
constituents that may account for bioactivity during influenza infection are not known.  
Given the challenges of protecting the population against influenza by large scale rapid 
vaccination efforts, it would be worthwhile to determine if a readily available botanical 
product may have therapeutic potential.  
              Influenza virus causes acute contagious respiratory disease by attaching and infecting 
epithelial cells lining the respiratory tract (Lamb et al., 1996). The initial host defense 
response involves activation of innate immunity to restrict spread of the virus by producing 
pro- inflammatory cytokines/chemokines (IFNα/β, IL-1, IL-6, and TNFα) from epithelial 
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cells, alveolar macrophages and DC (Ronni et al., 1997; Sareneva et al., 1998). Along with 
these cytokines, influenza virus infection also have been shown to upregulate the mRNA 
level of MCP-1, MIP-1α, MIP-1β, RANTES, IP-10, MIP (neutrophils attractant) and MIP-3α 
(immature DC) (Wareing et al., 2004). These inflammatory cytokines and chemokines 
induce an infiltration of inflammatory cells including monocytes, macrophages, neutrophils 
to the respiratory tract, along with activation of NK cells (Nguyen et al., 2004) and induction 
of febrile response (Wareing et al., 2004).  Dendritic cells (DC),  especially conventional 
dendritic cells (cDC) detect viral antigen, undergo maturation and migrate to draining lymph 
nodes for antigen presentation and induction of subsequent adaptive immune response 
(Grayson et al., 2007). Dendritic cells also produce IL-12 which promotes the development 
of an effective adaptive immune response by differentiation of naïve CD4 cells in to T helper 
1 (Th1) cells (Abbas et al., 1996). Th1 cells secrete cytokines that promote maturation and 
activation of CD8
+
 cytotoxic lymphocytes which are critical in viral clearance.  Th1 
cytokines promote antibody production, and antibody has an important role in preventing re-
infection from the same or related virus strain (Mosmann et al., 1996; Ridge et al., 1998; Ada 
et al., 1986). Cytotoxic T lymphocytes and virus specific antibody are very important factors 
in clearance of virus in a primary infection (Miao et al., 2010). Viral specific cytotoxic T 
lymphocytes attack and destroy infected cells primarily by Fas and perforin mediated 
mechanisms (Topham et al., 1997). Although direct activation of effector CD8
+
 cells is 
responsible for viral clearance, it is possible that an indirect effect such as modulation of 
innate immune parameters ultimately results in enhanced CD8
+
 response.  Therefore, agents 
that modulate either innate or adaptive immune response against influenza may be beneficial 
for the host.   
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    Echinacea extracts have been shown to activate non specific innate immune 
responses by stimulating inflammatory cytokine (TNFα, IL-1α, IL-6, and IL-12) and nitric 
oxide (NO) production by macrophages (Sullivan et al., 2008). Another study demonstrated 
that Echinacea likely modulates both innate and adaptive immunity by increasing production 
of multiple cytokines (IL-1β, IL-4, IL-10, and TNFα) (Zhai et al., 2007). A study by Pillai et 
al., (2007) reported that aqueous extract of Echinacea (rich in polysaccharide) increased 
CD4
+
 T helper cell activation, and CD4
+
 cells secrete cytokines that play a major role in 
maintaining cytolytic T cell function and the transition from effector to memory phase. 
Increased NK cell cytotoxicity and T cell proliferation have also been reported with use of 
different Echinacea extracts.  Although there are multiple studies demonstrating that 
Echinacea modulates immunity, very few studies have been designed to determine the 
efficacy of Echinacea during a respiratory infection, or determine whether a specific change 
of immune response is beneficial with respect to disease outcome.  Also, different Echinacea 
species and different types of extracts have not been compared simultaneously in a 
respiratory infection model.  One recent study (Fusco et al., 2010) did assess one type of 
Echinacea extract in an influenza model.  In this study there was less weight loss in the 
Echinacea-treated mice but no change in viral titer, suggesting a modifying effect of the 
extract on clinical course of infection (less body weight loss) without any evident anti-viral 
effect.  In this same study, at the early phase of infection (day 3) a decrease in lung KC, IL-5, 
and IL-10 was found in Echinacea treated mice.  By day 7 post-infection, Echinacea 
treatment resulted in reduced IL-10 in serum and lung, as well as decreased serum IFNγ.  It is 
not clear from this study how the immunomodulatory changes might relate to the reduction in 
weight loss, or to specific immunopathology in the lungs.   
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To our knowledge, the effect of different Echinacea extracts on the 
immunomodulatory response to influenza has not been studied.  The advantage of evaluating 
different species and/or types of extract preparation is that this approach will likely provide 
more information with respect to the constituents that may be responsible for bioactivity. The 
purpose of our investigation was to determine if differences in Echinacea species and/or 
differences in type of extract would result in differential modulation of immune response to 
influenza viral infection.  We hypothesized that the aqueous extracts of Echinacea (typically 
rich in polysaccharides and polyphenols) would be more effective than ethanolic extracts of 
Echinacea in inducing increased immune activation in response to influenza infection.  
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Material and Methods 
 
 
Mice: Male BALB/c mice, at 6-8 weeks of age were used in all experiments. The mice were 
acclimated to the housing conditions in the animal care facility for at least one week before 
the start of experiments. Harlan 2014 rodent chow by Teklad diets was fed to mice. The Iowa 
State University committee on animal care has approved the animal procedures. Mice were 
assigned randomly to different treatment groups containing 10-12 mice per group (number 
varies with experiment but constant within experiment).  
Extracts: E. angustifolia (PI631285) and E. purpurea (PI649040 & PI631307) were 
harvested in USDA North central regional plant introduction station at Ames, IA (USA). 
Alcohol Extracts from the dried roots of these two Echinacea species were prepared by a 
soxhlet extraction method as described by Lalone et al, 2007. A Lipophilic metabolite profile 
of ethanol extracts was performed by Lankun Wu (2008) (Figure 11). Water extracts were 
prepared by boiling 6 g of dried root in 100 ml of endotoxin free water in an endotoxin free 
flask, and stirred for 1 hour at room temperature.  Extracts were filtered using endotoxin free 
glass filter paper, centrifuged for 15 min at 10,000 rpm and pellets discarded before freeze 
drying. Endotoxin analysis of water extracts showed that the E. angustifolia extract used in 
this study had 1172.6 EU/ml whereas E. purpurea water extract had 131.6 EU/ml). The 
ethanol extract of E. angustifolia had a non detectable level of endotoxin and the ethanol 
extract of E. purpurea had 49.9 EU/ ml. The biological significance of these levels of 
endotoxin has not been thoroughly evaluated. Extracts were diluted to 14.67 mg/ml of 
extract, and the final concentration of the diluted extract was less than 5%. Each mouse was 
gavaged at a dose corresponding to 110 mg/kg body weight. The vehicle treated group was 
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gavaged using equal volume of <5% ethanol vehicle or water.  The gavage was performed 24 
hrs and 48 hrs prior to infection and continued every 24 hrs after infection until 
euthanization.   
Viral infection:  Mice were anesthetized with either CO2 or isoflurane and infected through 
an intranasal route with 25 µL of influenza A/PR/8/34 virus (sequence similarity to avian 
influenza virus isolates but less virulent) at a stock concentration of 10^
10.45
 EID using 
dilutions ranging from 1:1 to 1:8 resulting in a low dose infection (~5% mortality) to a high 
dose infection (~ 75% mortality).  Mice were housed separately after infection so that body 
weight, food, and water consumption could be measured every 24 hours.  
Viral titer quantification:  Virus titers were measured by quantitative fluorogenic real-time 
reverse-transcription polymerase chain reaction (RT-PCR) with TaqMan chemistry. Using 
sequences deposited in GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) and the 
Influenza Sequence Database (http://www.flu.lanl.gov), we engineered virus-specific 
oligonucleotide primers and a fluorescent probe to target a highly conserved region of the 
swine influenza virus nucleoprotein. The forward primer (SIVRTF:5_-
CGGACGAAAAGGCAACGA-3_) and reverse primer (SIVRTR:5_-
CTGCATTGTCTCCGAAGAAATAAG-3_) were synthesized by a commercial vendor 
(Integrated DNA Technologies). A TaqMan MGB probe with a 5_ reporter 6-
carboxyfluorescein (FAM) and a 3_ nonfluorescent quencher (SIVRTP: 5_-6- from 50 mL of 
lung and Bronchiolar Alveolar Lavage Fluid sample, positive control (H1N1 and H3N2 
swine influenza viruses) and negative control (elution buffer) using the Ambion MagMAX 
Viral RNA Isolation FAMCCGATCGTGCCYTC) was synthesized by Applied Biosystems. 
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To conduct the assay, viral RNA was first extracted Kit (Applied Biosystems) and 
KingFisher 96 magnetic particle processor (Thermo Scientific). Real-time RT-PCR was then 
carried out with the QuantiTect Probe RT-PCR Kit (Qiagen) in a 20 ml reaction volume 
using 4 mL of extracted template. Primers were added at a final concentration of 0.4 mmol/L 
each, and the probe was added at a final concentration of 0.2 mmol/L. Polymerase chain 
reaction amplification was performed on the ABI 7900HT Sequence Detection System 
(Applied Biosystems) with the 384-well format. Cycling conditions were as follows: (1) 
reverse transcription for 30 min at 50°C, (2) a 15 min activation step at 95 °C, and (3) 40 
cycles of 15 sec at 94_°C and 60 sec at 60_ °C. A set of influenza preparations, each with a 
known virus titer (EID50/mL), were used to generate a standard curve. Samples with 
threshold cycle values of 35 were considered positive. The amount of influenza in each 
sample was calculated by converting the threshold cycle value to a virus titer by using the 
standard curve. A limitation of using PCR for viral titer is that it does not differentiate live 
replicating virus from other viral particles.  
  
Bronchoalveolar Lavage and tissue collection:  Mice were euthanized and lungs were 
lavaged three times with 1 ml of phosphate buffered saline to collect bronchoalveolar fluid. 
The bronchoalveolar lavage (BAL) fluid was centrifuged, the supernatant was stored at -80 
°C for cytokine/chemokines analysis and viral titer quantification, and the BAL cells were 
collected for subsequent flow cytometric analysis of cell populations. Lung lobes were also 
collected after lavage in some experiments to determine viral titer. If lung lesion scoring 
(histopathology) was performed in the experiment, the whole lung was collected, fixed with 
10% formalin and analyzed for lung lesions by a pathologist blinded to treatment group. 
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Lung pathology: Lung tissue collected at necropsy was fixed in 10% buffered formalin for 
histopathological examination. After adequate fixation, the tissues were embedded in paraffin 
wax, sectioned at 5µm thickness, stained with hematoxylin-eosin, and examined with light 
microscopy. The lungs were examined for bronchiolar epithelial changes, including 
attenuation, proliferation, degeneration, and necrosis. Epithelial damage with influenza 
infection typically shows a range of degeneration, necrosis, sloughing and regeneration. The 
amount and severity of peribronchiolar and alveolar inflammation were also evaluated. 
Sections of lung were given a score from 0 to 3 to reflect an estimate of the percentage of 
lung tissue containing lesion and the severity of lesions, according to methods described 
elsewhere [Richt et al;2003]. The lung sections were scored according to the following 
criteria: 0, no significant lesions or minimal epithelial cells change in < 25% of the lung 
tissue; 1, mild to moderate epithelial cell changes and interstitial pneumonia in 25% to 50% 
of the tissue; 2, moderate epithelial cell changes and moderate interstitial pneumonia in 
~50% to 75% of the tissue; and 3, significant epithelial cell changes and moderate to severe 
interstitial to bronchio-interstitial pneumonia in ~75% to 100% of the tissue. For each mouse, 
the number of lung lobes examined and a score for each lobe was recorded. A single 
pathologist scored all slides and was blinded to the treatment groups. 
 
Cytokine/Chemokines analysis:  BAL supernatants were analyzed for cytokines and 
chemokines with a Luminex Platform (Bio-plex, Bio-rad) and a 32-plex kit (Millipore). 
Cytokines and chemokines included interleukin 1α (IL-1α), interleukin 1β (IL-1β), 
interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 
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6 (IL-6), interleukin 7 (IL-7), interleukin 9 (IL-9), interleukin 10 (IL-10), interleukin 12p40 
(IL-12p40), interleukin 12p70 (IL-12p70), interleukin 13 (IL-13), interleukin 15 (IL-15),  
interleukin 17 (IL-17), eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte 
macrophage colony-stimulating factor (GM-CSF), interferon-inducible protein 10(IP-10), 
IFN-γ, keratinococyte-derived chemokine (KC), monocytes chemo attractant protein 1 (MCP 
1), leukemia inhibitory factor ^ (LIF), LIX, macrophage inflammatory protein 1α (MIP 1α), 
macrophage inflammatory protein 1β (MIP-1β), RANTES (regulated on activation, normal T 
cell expressed and secreted), and tumor necrosis factor α (TNF α), macrophage colony 
stimulating factor (M-CSF), monokine-induced by interferon-  (MIG), macrophage 
inflammatory protein-2 (MIP-2), vascular endothelial growth factor (VEGF). 
 
Cell population Identification:  Cells isolated from the BAL fluid were stained with a 
combination of the following antibodies, (dependent upon the experiment): allophycocyanin–
cyanine 7–conjugated anti-mouse CD8α (53-6.7) for CD8a cells, fluorescein isothiocyanate–
conjugated anti-mouse CD11b and phycoerythrin-conjugated anti-mouse Gr1 in high side 
scatter population as neutrophils, or CD45
+
 (phycoerythrin- cyanine 7 rat anti-mouse CD45), 
Gr1-, CD11b- as lymphocytes. Appropriate isotype controls were used and cells were 
analyzed with BD FACSCanto flow cytometer (BD Biosciences).  Also, in some 
experiments, whole lungs were collected and analyzed for CD8
+
 cells that produced IFN  in 
response to influenza virus peptides. Briefly, lungs were homogenized, a single cell 
suspension was obtained, and cells were incubated at 37 °C for 6 hr with one of the 
following, medium alone, influenza NP peptide (NP 147-158, TYQRTRALVTG) or 
influenza HA peptide (HA 533-541, IYSTVASSLVL). Following the incubation, cells were 
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analyzed by flow cytometry using PE-conjugated anti-CD8α and intracellular APC-
conjugated anti-IFN  to identify activated CD8
+
 cells responding specifically to influenza 
virus. Protein transport inhibitor, Monensin, was used to increase accumulation of cytokine 
within cell by blocking their intracellular protein transport system 
 
Statistical analysis: A one-way analysis of variance was used to compare viral titer, lung 
lobe score, cytokine and chemokines levels, and cell populations at each day after infection. 
SPSS software (version 14.0; SPSS) was used in all analyses, and LSD post hoc analyses 
were performed as needed. To evaluate changes over time in body weight, food and water 
intake, a mixed analysis of variance (treatment group by repeated measures) was used. 
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Results                                               
Survival rate (Ethanol extract and water extract): 
            E. angustifolia ethanol extract treatment does not significantly improve the survival 
rate of mice infected with influenza virus compared to infected control mice treated with 
vehicle, when observed up to 8 days after infection (Fig 1a). On other hand, water extract of 
E. angustifolia from the same accession significantly improves the survival rate of infected 
mice when compared with the vehicle group (Fig 1b).  
 
BAL viral titer: 
          Viral titer was measured in all experiments. At day 1, 5, or 7 post-infection there was 
no significant effect of Echinacea treatment on the amount of virus in the BAL fluid or 
whole lung.  This held true regardless of whether E. angustifolia or E. purpurea was tested, 
and was also the case with either ethanol extracts or water extracts.  No effect on BAL viral 
titer was found with either extract of both Echinacea species tested (Fig 2a & 2b).  
 
Lung cytokine and chemokines (ethanol extracts): 
 The following cytokines and chemokines were shown to be significantly increased in 
the BAL fluid upon infection: exotaxin, GCSF, GMCSF, IFNγ, IL-1α, IL-1β, IL-2, IL-5, IL-
6, IL-10, IL-12p40, IL-15, IP-10, KC, LIF, LIX, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, 
RANTES and TNFα.  The following cytokines or chemokines were not significantly altered 
by infection at the time points measured in this study: IL-9, IL-13, IL-17; and the following 
cytokines were not detectable: IL-3, IL-4, and IL-7.  At day 5 of infection with influenza 
virus, E. angustifolia treatment induced a modest increase in IL-15 and GM-CSF, with a 
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trend (p <0.10) towards increased IL-12p40,  IL-10, and MIP-2 as compared to infected mice 
treated with vehicle (Fig 3a, 3b & 3c). In contrast, E. purpurea-treated mice did not have 
significantly different levels of cytokines/chemokines than vehicle-treated mice, but did 
show a trend towards increased GM-CSF (p=0.09) (Fig 4a, 4b & 4c).   Given that E. 
purpurea ethanol extract treatment appeared to be less effective in modulating cytokines as 
compared to E. angustifolia ethanol extract, further testing at day 7 post infection was done 
only with E. angustifolia ethanol extract. Similar to the findings at day 5, IL-10 tended to be 
increased in E. angustifolia treated mice at day 7 post-infection; however, the general trend 
was towards a decrease in multiple cytokines and chemokines (Fig 5a, 5b & 5c). At same 
time, parameters for illness severity such as weight loss and food intake were similar 
between the groups, ruling out a change in infection severity between the groups. 
 
Lung cytokine and chemokines (water extracts): 
            At day 5 of infection with influenza virus, the effect of E. angustifolia water extract 
was more evident, with significantly increased in a total of 13 cytokines or chemokines (IL-
1α, IL-12p40, TNFα, IL-5, GCSF, IL-6, KC, MCP-1, MIP-1β, MIP-2, IP-10, LIF, MIG) (Fig 
6a, 6b& 6c) as compared to vehicle treated mice.  The magnitude of water extract-induced 
changes was greater than ethanol extracts, and the water extracts appeared to affect many 
more cytokines and chemokines as compared to the ethanol extracts of same species.    
 
BAL lung cell populations: 
      At day 5 post-infection, treatment with E. angustifolia ethanol extract or E. 
purpurea ethanol extract did not alter lung cell populations even though chemokine 
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differences existed at this time point.  However, at day 7 post-infection, E. angustifolia 
ethanol treatments resulted in significantly fewer neutrophils (Fig 7a) but total lymphocyte 
number was not different.  With respect to water extract, at day 5 post-infection, there were 
also significantly fewer neutrophils (Fig 7b).  Therefore, the increase in chemokines did not 
appear to result in greater cell recruitment, but rather a reduction in neutrophils.  There were 
no changes in total CD8
+
 cells in any experiments; however, at day 8 post-infection, 
differences were found in the percentage of influenza-specific IFN -producing CD8
+
 cells. E. 
angustifolia ethanol extract treated mice had significantly fewer CD8
+
 IFN -producing cells 
in response to NP peptide than vehicle (p < 0.05) (Fig 8a). A similar pattern of response was 
found with respect to HA peptide.  In contrast, treatment with water extract of E. angustifolia 
significantly (p < 0.05) increased CD8α+ IFNγ-producing cells in response to both NP and 
HA peptides.  The treatment with water extracts of E. purpurea resulted in a similar type of 
response as the E. angustifolia water extract (a trend toward increased CD8
+ IFNγ-producing 
cells in response to NP peptide, Fig 8b) 
 
Illness severity (body weight, food intake):  
There was no significant difference in body weight loss between mice treated with E. 
angustifolia ethanol extract, E. purpurea ethanol extract or vehicle when mice infected with 
influenza virus were weighed up to day 8 post infection (Fig 9a). Similarly, there was no 
difference in body weight loss in mice treated with E. angustifolia water extracts, E. 
purpurea water extract and vehicle group infected with influenza up to day 7 post infection 
(Fig 9b).  The food intake results paralleled the body weight results in that no significant 
effects of any of the Echinacea treatments were found. 
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Pathology: 
              At day 8 post-infection lung lesions scores were not different between E. 
angustifolia ethanol extract treated mice, E. purpurea ethanol extract treated mice, and 
vehicle treated mice (Fig 10).   
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Discussion 
              Although many studies have investigated the effect of Echinacea extracts on 
specific immune cell populations (macrophages, monocytes, NK cells, T cells in cell 
cultures), data on the impact of Echinacea in a relevant in vivo disease model are limited. To 
our knowledge, this is the first study to evaluate the effect of different Echinacea species and 
different types of extract in the same experimental influenza infection model.  The one 
similar study published to date used only aqueous extract from the aerial part of E. purpurea 
in a mouse model of influenza infection (Fusco et al., 2010). A separate study examined the 
effect of Echinacea during influenza infection, but Echinacea was just one of a multi-
component preparation, and therefore it was difficult to draw any specific conclusions about 
the role of Echinacea alone. Again, neither of these published studies compared different 
types of extracts from different species to better understand the potential bioactive 
constituents.  
            The findings from the present experiments suggested that water extract both from E. 
angustifolia and E .purpurea have a more pronounced effect on the immunomodulation of 
cytokines than ethanol extracts from the same species without affecting viral titer and course 
of infection during the early phase of infection.  In general, it appeared that water extracts 
have a non-specific stimulatory effect in that the majority of the cytokines and chemokines 
measured were found to increase (IL-1α, IL-5, IL-10, IL-12p40, TNFα, KC, MIP-1α, MIP-
1β, IP-10, GCSF, LIF, MIG, IFNγ), rather than a specific group of cytokines/chemokines. 
The extraction process plays an important role in isolating different phytochemical from the 
plant by the use of different type of solvents. Water extracts primarily retain hydrophilic 
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constituents rich in polysaccharides and some polyphenols whereas ethanol solvent used for 
alcoholic extracts results in retention of alkamides and some polyphenols. The polyphenols 
group in Echinacea can be extracted by ethanol-water solvent (Hall, 2003) but it can also be 
detected in only water and only ethanol extract. Although a phytochemical analysis of water 
extract used in our study was not available, the literature suggests that high molecular mass 
polysaccharides are the main component of water extracts from root of Echinacea plant.  
Polyphenols and alkamides constitute the ethanolic extract of Echinacea root. According to 
Matthias et al. (2004), alkamides, but not polyphenols are capable of crossing the intestinal 
barrier and thus only alkamides are considered bioavailable.  The ethanol extracts of 
Echinacea used in our experiments were analyzed for their lipophilic metabolite profile by 
our center (Lankun Wu, Dissertation p28). This analysis showed that E. angustifolia ethanol 
extract had a relatively high abundance of Amide 8, whereas E. purpurea extract had amide 
2, amide 3, amide 8, chen amide in equal abundance.  Therefore, it is possible  that the 
bioactivity observed in the water extracts was due primarily to polysaccharides whereas the 
activity in ethanol extracts may have been due to the alkamides, particularly alkamide 8, 
although further studies will be required to confirm this. 
The effect of ethanol extracts from both plant species with respect to enhancement of 
cytokines or chemokines was more modest than the effect of water extracts in the early days 
of infection. At day 5 post-infection, there was an increase in IL-15, GM-CSF, and IL-12p40, 
but at day 7 post-infection, a decrease in IL-1 , IL-6, KC, and eotaxin was found.  At both 
time points, there was a tendency towards increased IL-10.  Therefore, it is possible that 
ethanol extracts of E. angustifolia act to modestly enhance cytokine/chemokine expression in 
the early phase of infection, but then exhibit anti-inflammatory effects at the later phase of 
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infection. In contrast to E. angustifolia ethanol extract, the ethanol extracts from E. purpurea 
had no significant effects in the influenza model of infection. 
   Nearly all extracts of Echinacea tested resulted in increased KC expression in the 
early phase of infection (except E. purpurea ethanol extract). KC is considered an important 
neutrophil attractant.  However, findings from another study suggest that 
macrophage/monocyte recruitment and the chemokines involved in recruitment of these cells 
(MCP-1, MIP1α) may have a greater role in overall inflammation and survival than 
neutrophils (Dawson et al.,2000). Therefore, a change in neutrophil number as induced by 
Echinacea may not have a large impact on overall disease outcome. Water extracts of E. 
angustifolia and E. purpurea stimulated a wide range of pro-inflammatory cytokines (IL-1α, 
IL-5, IL-6, IL-12p40, and TNFα) and chemokines (KC, GCSF, MCP-1, MIP-1α, MIP-2, IP-
10). Pro-inflammatory cytokines, particularly IL-6 and TNFα are secreted by activated 
alveolar macrophages, and the finding that IL-6 and TNFα are increased in the BAL 
corresponds with other research on Echinacea in which water extracts have been shown to 
stimulate macrophage cytokine production in vitro (Burger et al., 1997; Sullivan et al., 2008, 
Goel et al., 2002).   Although activated macrophages may have some anti-viral effects, 
studies have shown that inflammatory monocytes and macrophages and the cytokines 
produced by these cells at the site of infection are major contributors to influenza-associated 
immunopathology (Lin et al., 2008).   In spite of the Echinacea-associated increase in 
multiple inflammatory cytokines, mortality did not increase, suggesting that the enhancement 
of multiple cytokines is not detrimental. Therefore, it is possible that E. purpurea or E. 
angustifolia water extracts alter in a beneficial manner the careful balance between 
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promoting a productive immune response through activation of inflammatory responses, yet 
limiting inflammatory-induced cell damage.  It is important to note that although water 
extracts of Echinacea altered cytokines and chemokine response, there was no change in 
viral load in the lungs, or an improvement in symptoms (body weight loss, food intake) up to 
day 5 post-infection.  However, E. angustifolia water extract treatment reduced mortality 
when assessed up to day 8 post-infection.  Therefore, it remains possible that in the later 
stages of infection (day 7-12) viral clearance is improved and/or symptoms of illness are 
attenuated by Echinacea water extract treatment. 
 In contrast to wide range of cytokines and chemokines increased with water extracts, 
the results showed that after influenza infection, during the transition from innate to adaptive 
host defense (~day 5 post-infection), only IL-15, IL-12, and IL-10 tended to be greater in 
BAL of mice treated with ethanol extract of E. angustifolia. IL-15 may promote NK cell 
activation and memory T cell survival (Nogusa et al., 2009), and therefore an increase in IL-
15 may enhance viral clearance by NK cells. Other studies have shown stimulation of NK 
cells by Echinacea extract (Currier et al., 2000; Brousseau et al., 2005) and it is possible that 
the mechanism of NK activation is IL-15 dependent.  However, it is important to note that by 
day 5 post-infection, viral clearances was not improved in ethanol extract-treated mice.  
Therefore, if NK cells have greater activation as a result of Echinacea treatment, it either 
occurs at a later time point or does not translate to more effective viral clearance.   With 
respect to cytotoxic T cell function, the results showed that influenza-stimulated production 
of IFN  in CD8
+
 cells was not enhanced by Echinacea ethanol extract.  Memory T cell 
survival was not assessed, and therefore in future studies it will be important to determine 
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whether the enhancement of IL-15 production has an effect on memory T cells. Finally, a 
trend toward increased production of IL-10 at day 5 and day 7 post-infection in E. 
angustifolia ethanol extract treated mice suggested there may be an earlier activation of 
regulatory mechanisms to limit inflammation to prevent further damage of lung tissue.  It is 
also noteworthy that E. purpurea ethanol extract did not show any activity in modulation of 
cytokine in mice infected with influenza virus. 
               Activation of certain cytokines and chemokines in the early phase of infection as a 
result of treatment with E. angustifolia ethanol extracts might be expected to result in influx 
of large number of immune cells to local tissue (lung).  However, no increase in total number 
of leukocytes in the BAL was found by day 7 post-infection, and treatment with E. 
angustifolia ethanol extract decreased neutrophil influx to lungs. A similar effect was 
observed with respect to influenza-stimulated IFN  producing CD8
+
 cells in the lungs of 
influenza infected mice treated with E. angustifolia ethanol extract.  There was a significant 
decrease in the influx of CD8
+
IFN producing cells to lungs with Echinacea ethanol treatment 
but no effect on IFN  production on a per cell basis (MFI).  Taken together, these findings 
suggest that ethanol extracts of E. angustifolia may exhibit anti-inflammatory activity in the 
later stages of infection.   
 The reduction in BAL neutrophil number was observed with both water and ethanol 
extracts of E. angustifolia.  The apparent inconsistency between early phase infection 
increases in neutrophil chemokines (KC) and later phase reductions in neutrophils number 
may be attributed to either a failure of cytokines to recruit cells (integrins or attachment 
failure) or may be a compensatory immune mechanism to prevent further lung 
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immunopathology. The contribution of neutrophils to lung injury has been demonstrated, but 
neutrophils have also been shown to limit the extent of influenza virus replication and disease 
progression in lungs (Tate et al., 2009). A decrease in neutrophils can result in enhanced viral 
replication, high mortality and severe illness, although our findings show no effect of extracts 
on viral titer, illness markers, or pathological lesion score between any of the extract 
treatments and vehicle control groups across multiple time points. It is possible that the 
neutrophil effect is more important during the earliest phase of infection (days 1-4), and by 
day 5-7, increase in CD8a
+
 cells and initiation of adaptive immune responses become more 
important in clearing virus, and therefore the Echinacea-induced decline in BAL neutrophil 
number at day 5-7 may not have a negative impact on infection outcome.  
              In contrast to ethanol extracts, E. angustifolia water extract increases the number of 
influenza specific IFNγ producing CD8+ cells in the lungs at day 7 post- infection. Similarly, 
water extracts of E. purpurea tended to increase IFNγ producing CD8+ cells.   There was no 
effect on IFN  production on a per cell basis (MFI) with use of either extract, rather an effect 
on number of cells.  These findings are consistent with wide range stimulation of pro-
inflammatory cytokines by treatment with water extracts of Echinacea. An increase in 
influenza-induced IFNγ-producing CD8+ cells may be expected to result in a more rapid viral 
clearance.  It is possible that viral clearance was improved at a later time point (8-10 days 
post-infection), but viral load was not assessed at these later time points in our experiments.  
              Overall, the findings from these experiments show that water extracts and ethanol 
extracts prepared from the same species of Echinacea have very different effects in vivo.  
This is likely due to the differing constituents that are expected to be present in water extracts 
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(polysaccharides and polyphenols) as compared to ethanol extracts (alkamides and some 
polyphenols).  The in vivo effect of ethanol extracts is consistent with other in vitro results 
from our research group in that anti-inflammatory effects were observed (although these 
were confined to the later stages of infection).  Alkamides have been shown to be present in 
the ethanol extracts used in these experiments and may account for anti-inflammatory 
properties.  The constituents present in water extracts used in these studies are not yet 
available, but based on research from other groups, it is likely that water extracts contain 
polysaccharides (and polyphenols) which appear to exhibit immunostimulatory effects.  
Finally, it is important to note that although immunomodulatory effects were observed, there 
was no reduction in viral load in the lungs up to day 5 post-infection (with peak viral titers 
expected between day 2-4 post-infection).   It remains possible that benefits would be 
observed in the resolution phase of infection (day 10-14), and those experiments are the 
focus of future research.  It is also possible that the active fractions in each extract interact in 
such a way with each other or constituents of diet as to nullify the effects of each other, 
resulting in no change in symptom severity.  Again, further work will seek to identify the role 
of specific bioactive components.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a: Survival rate of mice treated with ethanol extract of Echinacea angustifolia 
(E.ang EtOH) at day 8 after infection. 10 mice per group were used and were infected with 
influenza virus. 5% ethanol was used for vehicle group and E. angustifolia ethanol extract 
was gavaged in the E.ang EtOH group.
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Figure 1b: Survival rate of mice treated with water extract of Echinacea angustifolia (E. ang 
H2O) at day 7 after infection. 10 mice per group were used and were infected with influenza 
virus. Water was used for vehicle group and E. ang H2O- E. angustifolia water extract was 
gavaged.  Survival rate in the E. ang EtOH groups was significantly higher than the vehicle 
treated group (p<0.05). 
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Figure 2a: Viral titer at day 5 post infection using ethanol extract of Echinacea angustifolia 
and Echinacea purpurea. 10-12 mice per group were used and lungs were collected to run 
RT-PCR for quantification of virus. 5% ethanol used as vehicle. E.ang EtOH- E. angustifolia 
ethanol extract, E. pur EtOH- E. purpurea ethanol extract.  There were no significant 
differences between treatment groups. 
 
 
 
Day 5
L
o
g
 v
ir
a
l 
ti
te
r 
(E
ID
5
0
5
0
/m
l)
1e+6
1e+7
1e+8
1e+9
1e+10
vehicle 
E.ang EtOH 
E.pur EtOH 
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2b: Viral titer at day 5 post infection using water extract of Echinacea angustifolia 
and Echinacea purpurea. 10-12 mice per group were used and lungs were collected to run 
RT-PCR for quantification of virus. 5% ethanol used as vehicle. E.ang H2O= E. angustifolia 
water extract, E. pur H20= E. purpurea water extract.  There were no significant differences 
between treatment groups. 
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Figure 3a: Cytokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea angustifolia. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
using 32-plex kit. E.ang EtOH= E. angustifolia ethanol extract. (*-p<0.05; +-p<0.1)
GM-CSF IL-1a IL-1b IL-5 IL-10 IL-12p40 IL-15 TNFa
p
g
/m
l
0
20
40
60
80
100
120
vehicle 
E.ang EtOH 
*
*
+
+
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3b: Cytokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea angustifolia. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
32-plex kit. E.ang EtOH= E. angustifolia ethanol extract. (+-p<0.1)
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Figure 3c: Cytokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea angustifolia. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
using 32-plex kit. E.ang EtOH= E. angustifolia ethanol extract. 
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Figure 4a: Cytokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea purpurea. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
using 32-plex kit. E.pur EtOH= E. purpurea ethanol extract. (+-p<0.1)
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Figure 4b: Chemokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea purpurea. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
using 32-plex kit. E.pur EtOH= E. purpurea ethanol extract. There were no significant 
differences between groups.
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Figure 4c: Chemokine profile in BAL fluid at day 5 post infection using Ethanol extract of 
Echinacea purpurea. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 5 days of infection with influenza and was analyzed 
using 32-plex kit. E.pur EtOH= E. purpurea ethanol extract.  There were no significant 
differences between groups. 
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 Figure 5a: Cytokine profile in BAL fluid at day 7 post infection using Ethanol extract of 
Echinacea angustifolia. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 7 days of infection with influenza and was analyzed 
using 32-plex kit. E.ang EtOH= E. angustifolia ethanol extract. (*-p<0.05; +-p<0.1) 
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Figure 5b: Cytokine profile in BAL fluid at day 7 post infection using Ethanol extract of 
Echinacea angustifolia. Vehicle group was gavaged with 5% ethanol.10-12 mice per group 
were assigned. BAL was collected after 7 days of infection with influenza and was analyzed 
using 32-plex kit. E.ang EtOH= E. angustifolia ethanol extract. (*-p<0.05; +-p<0.1)
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Figure 5c: Cytokine profile in BAL fluid at day 7 post infection using ethanol extract of 
Echinacea angustifolia. 10-12 mice per group were used. Ethanol 5% was used as vehicle 
and E.ang EtOH- ethanol extract of E. angustifolia. (*-p<0.05; +-p<0.1) 
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Figure 6a: Cytokine profile in BAL fluid at day 5 post infection using water extract of 
Echinacea angustifolia. Vehicle group was gavaged with water. 10-12 mice per group were 
assigned. BAL was collected after 5 days of infection with influenza and was analyzed using 
32-plex kit. Significant increase in wide range of cytokines and chemokines was observed in 
group gavaged with extract. E. ang H2O= E. angustifolia water extract. (*-p<0.05; +-p<0.1)
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Figure 6b: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea angustifolia. Vehicle group was gavaged with water. 10-12 mice per 
group were assigned. BAL was collected after 5 days of infection with influenza and was 
analyzed using 32-plex kit. Significant increase in wide range of cytokines and chemokines 
was observed in group gavaged with extract. E. ang H2O= E. angustifolia water extract. (*-
p<0.05) 
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Figure 6c: Cytokine profile in BAL fluid at day 5 post infection using water extract of 
Echinacea angustifolia. Vehicle group was gavaged with water 10-12 mice per group were 
assigned. BAL was collected after 5 days of infection with influenza and was analyzed using 
32-plex kit. Significant increase in wide range of cytokines and chemokines was observed in 
group gavaged with extract. E. ang H2O= E. angustifolia water extract. (*-p<0.05; +-p<0.1) 
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Figure 7a: Cell population in BAL Fluid after treatment with ethanol extract of E. 
angustifolia and E. purpurea at day 5 and day 7 of infection with influenza virus. BAL cells 
were stained for surface markers and determined by flow cytometry. 10-12 mice per group 
were used. Ethanol 5% was used to gavage vehicle group. E.ang EtOH= E. angustifolia 
Ethanol extract, E. pur EtOH= E. purpurea Ethanol extract. Note that at Day 7 experiment, 
E. purpurea Ethanol extract was not tested. (*-p<0.05) 
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Figure7b: Cell population in BAL Fluid after treatment with water extract of E. angustifolia 
at day 5 of infection with influenza virus. BAL cells were stained for surface markers and 
determined by flow cytometry. 10-12 mice per group were used. Water was used to gavage 
vehicle group.  E. ang H2O= E. angustifolia water extract. (*-p<0.05) 
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Figure 8a: Percentage of CD8
+ cells producing IFNγ in response to in vitro stimulus in lung 
of mice infected with Influenza at Day 7 Post infection and gavaged with Ethanol Extract of 
E. angustifolia. 10-12 mice per group were used and lungs were collected for intra-cell 
staining. Stimuli in vitro was from Influenza virus specific peptides- HA and NP. Staining 
was done CD8
+
 surface marker and intra cell for IFNγ production and samples run under 
flow cytometry. Vehicle= ethanol 5%, E. ang EtOH- ethanol extract of E. angustifolia.  
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  Figure 8b: Percentage of CD8+ cells producing IFNγ in response to in vitro stimulus in lung 
of mice infected with Influenza at Day 7 post infection and gavaged with water extract of E. 
angustifolia and E. purpurea. Treatment groups contained 10-12 mice. Stimuli in vitro was 
influenza virus specific peptides- HA and NP. Vehicle group was gavaged with water. E. ang 
H2O= E. angustifolia water extract, E. pur H2O= E. purpurea water extract. (*-p<0.05; +-
p<0.1) 
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Figure 9a: Body weight graph of mice infected with influenza virus for day 8 post infection. 
10-12 mice were assigned to each treatment group, infected with influenza virus and gavaged 
and weighed throughout the course of infection. Vehicle group was gavaged with 5% ethanol 
and extract group was gavaged with either E. ang EtOH or E. pur EtOH extract. E. ang 
EtOH= ethanol extract of E. angustifolia, E. pur EtOH= ethanol extract of E. purpurea.
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Figure 9b: Body weight graph of mice infected with influenza virus for day 7 post infection. 
10-12 mice were assigned to each treatment group, infected with influenza virus and gavaged 
and weighed throughout the course of infection. Vehicle group was gavaged with water and 
extract group was gavaged with either E. ang H2O or E. pur H2O. E. ang H2O= water 
extract of E. angustifolia, E. pur H2O= water extract of E. purpurea. 
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Figure 10: Lung lesion score graph of mice treated with ethanol extract of Echinacea for 8 
day after infecting with influenza virus. Each group was assigned with 12 mice. Vehicle 
group was treated with 5% ethanol only. Lung lobes were collected at day 8 of infection and 
fixed for histopathology exam. E. ang EtOH= ethanol extract of E. angustifolia, E. pur 
EtOH= ethanol extract of E. purpurea.
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Figure 11:   Relative abundance of lipophilic metabolites in E. angustifolia (PI631285) and 
E. purpurea (PI631307). Reference: Lankun Wu, Dissertation (2008)                
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 CHAPTER THREE: CONCLUSION 
              
             Taking into consideration all of the findings from multiple experiments, we can make 
general comments on the immune modulating properties of Echinacea extracts in an in vivo 
model of influenza infection. The overall results based on experiments using two Echinacea 
species (E. angustifolia and E. purpurea) show that water extracts improve the survival rate 
of infected mice and are more immunomodulatory as compared to ethanol extracts, even 
within the same species. Improvement of survival rate in water extract-treated mice may be 
explained by the early increase of inflammatory mediators resulting in a more rapid or potent 
innate cell recruitment. As a result, there may be increased antigen presenting cell activation 
and/or T helper cell activation that are essential for optimal CD8
+
 effector function and 
expansion. Our results have shown that water extract treatment of infected mice resulted in 
an increased influx of influenza specific CD8
+
 effector cells to the lungs at day 8 of infection.  
CD8
+
 effectors play critical role in viral clearance and potentially improving the survival 
rate. The effects on CD8
+
 cell activation as assessed by IFNγ production may result from an 
Echinacea-induced activation of innate host defenses that occurs in the first several days of 
infection.  Further support for this possibility will be tested in future studies in which CD8
+
 
effector cell-mediated viral clearance is measured. These results suggest that different 
solvents used in the extraction process may result in the retention of different bioactive 
components of Echinacea. Polysaccharides and some polyphenols have been shown to be 
present in water extracts while alkamides are main component of ethanol extract.  Other data 
from the botanical center clearly shows that alkamides and some polyphenols are present in 
the ethanol extracts used in these experiments.  The alkamides and polyphenols may account 
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for the anti-inflammatory activity observed in ethanol extract treated mice at later phases of 
infection (reduced neutrophils and reduced IFNγ+ CD8+ cells in the lungs).  One major 
limitation of these findings is that information regarding the potentially bioactive constituents 
in the water extracts is not currently available.  However, the in vivo results with water 
extracts show immune stimulatory activity which is consistent with literature showing that 
polysaccharides (and polyphenols) present in water extracts are the immunostimulatory 
component of Echinacea extract. These results are consistent with earlier studies in different 
in vivo and in vitro models of infection.     
                   It is interesting to note that none of extracts used have any evidence of anti-viral 
activity during early phase of infection. However, if the mechanism by which E. angustifolia 
water extracts improve survival is through an enhancement of CD8+ effector function, then 
an improvement in symptoms and/or viral clearance may not be detectable until the later 
phases of infection (day 8-12). Another potential limitation of these studies is that only 
specific time points have been evaluated (days 1, 5, 7, 8 post-infection), and it is possible that 
the immune alterations that were observed do not translate into significant clinical 
improvements until the very later stages of infection and recovery (days 9-14). Finally, it is 
possible that an interaction of components in the rodent chow with constituents in the plant 
extracts may play a role in affecting host response. The experiments to address these 
questions are the focus of future research.  
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                                                                   APPENDIX 
 
Introduction 
           Preliminary experiments using both ethanol and water extracts of E. angustifolia and 
E. purpurea were conducted at low viral dose (~5% mortality). Infection at the low virus 
resulted in highly variable responses within the lung.  Viral titer varied by more than a log of 
3 and cytokine levels varied by greater than 10fold between infected mice.  With the large 
degree of variability, it was difficult to detect treatment effects although some general 
patterns emerge such that water extracts tended to increase cytokines and chemokines in the 
BAL.  Extract treatment did not reduce viral load in the lungs.  At this low dose of infection, 
weight loss did not occur. 
            Water and ethanol of both E. angustifolia and E. purpurea were used for treatment of 
mice.  Mice were gavaged 24 and 48 prior to infection, and every 24 hours after infection up 
until the time of euthanization.  Lung viral titer quantification was performed after 5 day post 
infection in all the experiments, and cytokines in the BAL fluid were also assessed at 5 days 
post-infection.  
There was no significant difference of viral load in extract treatment group than in 
vehicle group with any of the extract from both Echinacea species (Fig 1a & 1b).   The effect 
of extract treatment on cytokine and chemokine profile in BAL fluid of mice infected with 
low virus dose at day 5 post infection was also analyzed using 32-plex kit. Treatment with 
ethanol extract of E. angustifolia significantly (p<0.05) decreased some of the cytokines and 
chemokines (LIX, RANTES, IP-10, IL-6) in lungs while MCP-1 and IL-5 show a trend 
(p<0.1) toward decrease as compared to vehicle group (Fig 2a, 2b & 2c). On other hand, 
79 
 
treatment with ethanol extract of E. purpurea has no effect on cytokine and chemokine in 
lungs than vehicle group (3a, 3b & 3c). BAL cell population was also not affected by ethanol 
extract treatment and was similar to vehicle group (Fig 6). 
               Similarly with water extract at day 5 post infection, no significant effects of either 
E. angustifolia (4a, 4b & 4c) or E. purpurea (5a, 5b & 5c) treatment on any of the cytokines 
or chemokines was measured. Also, no effect of ethanol or water extracts was observed with 
respect to body weight of mice infected with low virus dose (Fig 7a & 7b).  
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Figure 1a: Viral titer at day 5 post infection using ethanol extract of Echinacea angustifolia 
and Echinacea purpurea at low dose of viral infection.10-12 mice per group was used and 
lungs were collected to run RT-PCR for quantification of virus. Ethanol 5% was used as 
vehicle. E. ang EtOH= E. angustifolia ethanol extract, E. pur EtOH= E. purpurea ethanol 
extract. 
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Figure 1b: Viral titer at day 5 post infection using water extract of Echinacea angustifolia 
and Echinacea purpurea at low dose of viral infection. 10-12 mice per group were used and 
lungs were collected to run RT-PCR for quantification of virus. Water used as vehicle. E. ang 
H2O= E. angustifolia water extract, E. pur H20= E. purpurea water extract. (+-p<0.1) 
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Figure 2a: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea angustifolia at low dose of virus infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using multiplex kit. E. ang EtOH= E. 
angustifolia ethanol extract. (*-p<0.05; +-p<0.1)
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Figure 2b: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea angustifolia at low dose of virus infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using multiplex kit. E. ang EtOH= E. 
angustifolia ethanol extract. (+-p<0.1)
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Figure 2c: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea angustifolia at low dose of virus infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using multiplex kit. E. ang EtOH= E. 
angustifolia ethanol extract.  (*-p<0.05) 
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Figure 3a: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea purpurea at low dose of viral infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using 32-plex kit. E. pur EtOH= E. 
purpurea ethanol extract. (+-p<0.1) 
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Figure 3b: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea purpurea at low dose of viral infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using 32-plex kit. E. pur EtOH= E. 
purpurea ethanol extract. 
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Figure 3c: Cytokine and chemokine profile in BAL fluid at day 5 post infection using 
Ethanol extract of Echinacea purpurea at low dose of viral infection. Vehicle group was 
gavaged with 5% ethanol.10-12 mice per group were assigned. BAL was collected after 5 
days of infection with influenza and was analyzed using 32-plex kit. E. pur EtOH= E. 
purpurea ethanol extract. (+-p<0.1) 
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Figure 4a: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea angustifolia at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. ang H2O= E. angustifolia water 
extract.  
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Figure 4b: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea angustifolia at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. ang H2O= E. angustifolia water 
extract. 
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Figure 4c: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea angustifolia at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. ang H2O= E. angustifolia water 
extract. 
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Figure 5a: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea purpurea at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. pur H2O= E. purpurea water extract. 
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Figure 5b: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea purpurea at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. pur H2O= E. purpurea water extract. 
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Figure 5c: Cytokine and chemokine profile in BAL fluid at day 5 post infection using water 
extract of Echinacea purpurea at low dose of viral infection. Vehicle group was gavaged 
with water. 10-12 mice per group were assigned. BAL was collected after 5 days of infection 
with influenza and was analyzed using 32-plex kit. E. pur H2O= E. purpurea water extract. 
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Figure 6: Cell population in BAL Fluid after treatment with ethanol extract of E. 
angustifolia and E. purpurea at day 5 of infection with low dose of influenza virus. BAL 
cells were stained for surface markers and determined by flow cytometry. 10-12 mice per 
group were used. 5% ethanol was used to gavage vehicle group. E. ang EtOH= E. 
angustifolia Ethanol extract, E. pur EtOH= E.  purpurea Ethanol extract.  
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Figure 7a: Body weight graph of mice infected with low dose of influenza virus for day 5 
post infection. 10-12 mice were assigned to each treatment group, infected with influenza 
virus and gavaged and weighed throughout the course of infection. Vehicle group was 
gavaged with 5% ethanol and extract group was gavaged with either E. ang EtOH or E. pur 
EtOH. E. ang EtOH= ethanol extract of E. angustifolia, E. pur EtOH= ethanol extract of E. 
purpurea. 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
b
o
d
y
 w
e
ig
h
t 
(g
m
s
)
22
23
24
25
Vehicle 
E.ang EtOH 
E.pur EtOH 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7b: Body weight graph of mice infected with low dose of influenza virus for day 5 
post infection. 10-12 mice were assigned to each treatment group, infected with influenza 
virus and gavaged and weighed throughout the course of infection. Vehicle group was 
gavaged with water and extract group was gavaged with either E. ang H2O extract. E. ang 
H2O= water extract of E. angustifolia.       
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